ERBB2 and breast carcinoma: Preclinical studies highlight their efficacy in HER2+ breast cancer models, where phosphatase-cleavable ADCs outperformed both Val-Cit-PABC-based conjugates and the non-cleavable ADC T-DM1 in tumor suppression [85].